Pre-made Gimsilumab benchmark antibody ( Whole mAb, anti-CSF2 therapeutic antibody, Anti-CSF/GMCSF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gimsilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor (GM-CSF), which is a myeloid cell growth factor and pro- inflammatory cytokine. ... Inhibition of GM-CSF may be able to reverse this pathology.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-244-1mg	1mg	3090
GMP-Bios-ab-244-10mg	10mg	Inquiry
GMP-Bios-ab-244-100mg	100mg	Inquiry
GMP-Bios-ab-244-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gimsilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
INN Name	Gimsilumab
Target	CSF2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Ludwig Institute for Cancer Research;Morphotek
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Cancer;Rheumatoid arthritis
Development Tech	MORPHODOMA Technology